Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6551-6559

  Ueda, Ryo ^a,b   Fujita, Mitsugu ^a,b   Zhu, Xinmei ^a,b   Sasaki, Kotaro ^a   Kastenhuber, Edward R ^b   Kohanbash, Gary ^a,b   McDonald, Heather A ^b   Harper, Jay ^c   Lonning, Scott ^c   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHA2 (671-679) PEPTIDE VACCINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GARC 1 (77-85) PEPTIDE VACCINE; GLIOMA ASSOCIATED ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; SMAD2 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; GLIOMA; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; GLIOMA; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; VACCINES, SUBUNIT;

EID: 70350708139     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1067     Document Type: Article

References (51)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
2. Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma-genes, viruses, and vaccines. Neurosurg Rev 2008;31: 141-55; discussion 155.
3. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, et al. Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 2006;66:5883-5891 (Pubitemid 43927143)
4. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004;2:40. (Pubitemid 40617850)
5. Ueda R, Kinoshita E, Ito R, Kawase T, Kawakami Y, Toda M. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. I nt J Cancer 2008;122: 2274-2279 (Pubitemid 351542331)
6. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009;29: 1-42.
7. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006;25:455-471 (Pubitemid 44354214)
8. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916-3920
9. Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8: 369-380 (Pubitemid 41579832)
10. Ranges GE, Figari IS, Espevik T, Palladino MA, Jr. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 1987;166:991-998 (Pubitemid 18024241)
11. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cyto-toxicity through TGF-β signals in vivo. Proc Natl Acad Sci U S A 2005;102:419-424 (Pubitemid 40116782)
12. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-2093 (Pubitemid 46211385)
13. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, et al. Immunosuppression and transforming growth factor-β in glioblastoma. Pr eferential production of transforming growth factor-β 2. J Immunol 1989;143:3222-3229 (Pubitemid 20010149)
14. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992;148:1404-1410
15. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11: 5515-5525
16. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-1122
17. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, et al. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007;67:2351-2359 (Pubitemid 46424257)
18. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD- 208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-7961 (Pubitemid 39446929)
19. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003;63:8487-8491
20. Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 2006;118:942-949 (Pubitemid 43157669)
21. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclona l antibodies recognizing transforming growth factor-β. Bio activity neutralization and transforming growth factor β2 affinity purification. J Immunol 1989;142:1536-1541 (Pubitemid 19086319)
22. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, et al. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 2006; 66:4478-4487
23. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007;67:6451-6458 (Pubitemid 47037530)
24. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Tol l like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007;5:10. (Pubitemid 46351580)
25. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, et al. In hibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological micro-environment in a murine intracranial glioma. J Immunol 2008;180:2089-2098
26. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-987 (Pubitemid 40478567)
27. Leivonen SK, Kahari VM. Transforming growth factor-β signaling in cancer invasion and metastasis. Int J Cancer 2007;21:2119-2124 (Pubitemid 47585589)
28. Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-693 (Pubitemid 41740650)
29. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146 (Pubitemid 37328691)
30. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL- 15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827-4831 (Pubitemid 34495942)
31. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-3302
32. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, et al. CD 4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121:95-105. (Pubitemid 46753856)
33. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4 +CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol 2007;178:2883-2892
34. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008;83: 1136-1144 (Pubitemid 351960345)
35. Pardoux C, Ma X, Gobert S, Pellegrini S, Mayeux P, Gay F, et al. Downregulation of interleukin- 12 (IL-12) responsiveness in human T cells by transforming growth factor-β: relationship with IL-12 signaling. Blood 1999;93: 1448-1455
36. Trinchieri G. Interleukin -12: a cytokine produced by antigen-presenting cells with immuno-regulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-4027 (Pubitemid 24371902)
37. Maeda H, Shiraishi A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-78 (Pubitemid 3024752)
38. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-345
39. Lucas PJ, Kim SJ, Mackall CL, Telford WG, Chu YW, Hakim FT, et al. Dysregulation of IL-15-mediated T-cell homeostasis in TGF-β dominant-negative receptor transgenic mice. Blood 2006;108:2789-2795
40. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effect or memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-9576 (Pubitemid 40981722)
41. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 1992;76: 799-804.
42. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, et al. The effect of transforming growth factor-β2-specific phosphorothioate- anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944-951 (Pubitemid 23159332)
43. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine- activated killer cells. Cancer Immunol Immunother 1993;36:409-416 (Pubitemid 23146829)
44. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68:3835-3843
45. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915-3923
46. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin Cancer Res 2009;15:6560-6569
47. Liu Y, Wang Q, Kleinschmidt-DeMasters BK, Franzusoff A, Lillehei Ng KY. TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol 2007;81:149-162 (Pubitemid 44963973)
48. Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008;195:21-27
49. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, et al. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860-1864 (Pubitemid 36460849)
50. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res 2008;68:10247-10256
51. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 2008;14:3966-3974